MA46428B1 - Composés de pth à libération contrôlée - Google Patents

Composés de pth à libération contrôlée

Info

Publication number
MA46428B1
MA46428B1 MA46428A MA46428A MA46428B1 MA 46428 B1 MA46428 B1 MA 46428B1 MA 46428 A MA46428 A MA 46428A MA 46428 A MA46428 A MA 46428A MA 46428 B1 MA46428 B1 MA 46428B1
Authority
MA
Morocco
Prior art keywords
controlled
pth
release
compound
release pth
Prior art date
Application number
MA46428A
Other languages
English (en)
Other versions
MA46428A (fr
Inventor
Kennett Sprogøe
Lars HOLTEN-ANDERSEN
David Brian KARPF
Original Assignee
Ascendis Pharma Bone Diseases A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma Bone Diseases A/S filed Critical Ascendis Pharma Bone Diseases A/S
Publication of MA46428A publication Critical patent/MA46428A/fr
Publication of MA46428B1 publication Critical patent/MA46428B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques comprenant un composé de parathormone (PTH) à libération contrôlée ou un sel pharmaceutiquement acceptable, un hydrate ou un solvate de celui-ci, destiné à être utilisé dans un procédé de traitement, de contrôle, de retardement ou de prévention d'une affection qui peut être traitée, contrôlée, retardée ou empêchée avec la PTH, la composition pharmaceutique comprenant le composé de PTH à libération contrôlée étant administrée conformément à un régime posologique dans lequel le réglage de la dose en réponse à l'hypocalcémie ou à l'hypercalcémie est effectué par incréments de pas plus de 25 %.
MA46428A 2016-09-29 2017-09-28 Composés de pth à libération contrôlée MA46428B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16191453 2016-09-29
EP17781426.6A EP3518982B1 (fr) 2016-09-29 2017-09-28 Composés de pth à libération contrôlée
PCT/EP2017/074593 WO2018060311A1 (fr) 2016-09-29 2017-09-28 Schéma posologique incrémentiel dans des composés de pth à libération contrôlée

Publications (2)

Publication Number Publication Date
MA46428A MA46428A (fr) 2019-08-07
MA46428B1 true MA46428B1 (fr) 2025-02-28

Family

ID=57042754

Family Applications (1)

Application Number Title Priority Date Filing Date
MA46428A MA46428B1 (fr) 2016-09-29 2017-09-28 Composés de pth à libération contrôlée

Country Status (19)

Country Link
US (1) US12453778B2 (fr)
EP (2) EP3518982B1 (fr)
JP (3) JP7039574B2 (fr)
CN (2) CN109789221B (fr)
AU (3) AU2017336250C1 (fr)
CA (1) CA3037444A1 (fr)
DK (1) DK3518982T3 (fr)
ES (1) ES3012647T3 (fr)
FI (1) FI3518982T3 (fr)
HR (1) HRP20250102T1 (fr)
HU (1) HUE070273T2 (fr)
LT (1) LT3518982T (fr)
MA (1) MA46428B1 (fr)
PL (1) PL3518982T3 (fr)
PT (1) PT3518982T (fr)
RS (1) RS66518B1 (fr)
SI (1) SI3518982T1 (fr)
SM (1) SMT202500059T1 (fr)
WO (1) WO2018060311A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL317744A (en) * 2016-03-01 2025-02-01 Ascendis Pharma Bone Diseases As PTH drug agonists
PL3518961T3 (pl) 2016-09-29 2023-08-14 Ascendis Pharma Bone Diseases A/S Związki pth o niskim stosunku wartości maksymalnej do minimalnej
FI3518982T3 (fi) * 2016-09-29 2025-02-11 Ascendis Pharma Bone Diseases As Säädellysti vapautuvia PTH-yhdisteitä
RS64440B1 (sr) 2016-09-29 2023-09-29 Ascendis Pharma Bone Diseases As Režim doziranja za pth jedinjenje sa kontrolisanim oslobađanjem
CN119504973A (zh) * 2018-03-28 2025-02-25 阿森迪斯药物肿瘤股份有限公司 Il-2缀合物
CA3099620A1 (fr) * 2018-05-18 2019-11-21 Ascendis Pharma Bone Diseases A/S Dose initiale de conjugues de la pth
US12403182B2 (en) 2019-02-11 2025-09-02 Ascendis Pharma Bone Diseases A/S Liquid pharmaceutical formulations of PTH conjugates
CN115003320A (zh) * 2020-01-13 2022-09-02 阿森迪斯药物骨疾病股份有限公司 甲状旁腺功能减退的治疗
IL298642A (en) 2020-06-03 2023-01-01 Ascendis Pharma Oncology Div A/S il-2 sequences and uses thereof
EP4217004A1 (fr) * 2020-09-28 2023-08-02 Ascendis Pharma Bone Diseases A/S Amélioration du bien-être physique et mental de patients atteints d'hypoparathyroïdisme
CA3251827A1 (fr) * 2022-05-11 2023-11-16 Alexion Pharmaceuticals, Inc. Dosage elisa de liaison à un peptide biotinylé à haute sensibilité
EP4593867A2 (fr) 2022-09-30 2025-08-06 Extend Biosciences, Inc. Parathormone à action prolongée

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744444A (en) 1989-10-27 1998-04-28 Haemopep Pharma Gmbh HPTH-fragment-(1-37), the preparation thereof, medicaments containing same and the use thereof
US5567439A (en) 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
ZA9811127B (en) 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US20050124537A1 (en) 2000-04-27 2005-06-09 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
EP1477496A4 (fr) * 2002-02-01 2006-08-02 Chugai Pharmaceutical Co Ltd Pth a liaison peg ou derive de pth a liaison peg
US6559293B1 (en) 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
AU2002951372A0 (en) * 2002-09-13 2002-09-26 St Vincent's Institute Of Medical Research Parathyroid hormone-like polypeptides
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
CA2521784C (fr) 2003-04-08 2012-03-27 Yeda Research And Development Co. Ltd. Medicaments pegyles reversibles
US7690003B2 (en) 2003-08-29 2010-03-30 Fuller Jeffrey C System and method for increasing data throughput using thread scheduling
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
WO2005099768A2 (fr) 2004-03-23 2005-10-27 Complex Biosystems Gmbh Lieur de promedicaments
CN101151048A (zh) 2004-05-10 2008-03-26 纳斯泰克制药公司 增强甲状旁腺激素粘膜递送的组合物和方法
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
CN1597697A (zh) 2004-07-19 2005-03-23 中国药科大学 一种人的甲状旁腺素1－34肽相关肽－Pro－Pro－[Arg11]]hPTH(1－34)－Pro－Pro
US20060069021A1 (en) 2004-08-13 2006-03-30 Nastech Pharmaceutical Company Inc. Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
WO2006059237A1 (fr) 2004-08-30 2006-06-08 Lunamed, Inc. Formulations a liberation controlee d'acide 4-phenylbutyrique utilisees dans des traitements
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
CN1298386C (zh) * 2005-08-31 2007-02-07 上海交通大学 甲状旁腺激素缓释微球的制备方法
US20080176787A1 (en) 2005-09-06 2008-07-24 Paul Morley Parathyroid hormone analogues and methods of use
JP2009508820A (ja) * 2005-09-06 2009-03-05 ゼロス セラピューティクス， インコーポレイテッド 副甲状腺ホルモンアナログおよび使用法
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
CN101466393A (zh) * 2006-03-15 2009-06-24 阿尔扎公司 用于经皮递送甲状旁腺激素药剂以治疗骨质减少的方法
MX2009002859A (es) 2006-09-15 2009-03-30 Enzon Pharmaceuticals Inc Enlazadores biodegradables a base de ester impedido para suministro de oligonucleotidos.
BRPI0719885B8 (pt) 2006-10-13 2021-05-25 Lilly Co Eli peptídeos peguilados como moduladores de receptores de pth, seus usos, e composição.
US8101729B2 (en) 2007-03-19 2012-01-24 Henry Joseph Niemczyk Pegylated amino acid derivatives and the process to synthesize the same
ES2675174T3 (es) 2007-04-09 2018-07-09 The Board Of Trustees Of The University Of Arkansas Proteínas de fusión de un dominio de enlazamiento a colágeno y hormona paratiroidea
JP5351889B2 (ja) 2007-06-21 2013-11-27 テクニシェ ユニバーシタット ミュンヘン インビボおよび／またはインビトロ安定性が増大した生物学的に活性なタンパク質
EP2175878A4 (fr) 2007-07-11 2014-12-03 Belrose Pharma Inc Système d'administration de médicament polymérique contenant un groupement aromatique multi-substitué
EP2052736A1 (fr) 2007-10-26 2009-04-29 Nycomed Danmark ApS Formulations d'hormones parathyroïdiennes et leurs utilisations
CA2712224C (fr) * 2008-02-01 2016-03-08 Ascendis Pharma As Promedicament comprenant un conjugue medicament-lieur
HUE054585T2 (hu) * 2008-04-29 2021-09-28 Ascendis Pharma Endocrinology Div A/S Pegilezett rekombináns humán növekedési hormon vegyületek
US20110105413A1 (en) 2008-05-23 2011-05-05 Enzon Pharmaceuticals, Inc. Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides
JP5560266B2 (ja) 2008-06-06 2014-07-23 ダニスコ・ユーエス・インク バシルススブチリス（Ｂ．ｓｕｂｔｉｌｉｓ）由来アルファ‐アミラーゼを用いるデンプンからのグルコースの生産
WO2009156481A1 (fr) 2008-06-25 2009-12-30 Ascendis Pharma As Bnp pégylé
WO2010022171A1 (fr) * 2008-08-19 2010-02-25 Ferring International Center S.A. Agonistes du récepteur de pth peptidique
CN108530543B (zh) 2009-02-03 2023-06-23 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
EP2411038B1 (fr) * 2009-03-27 2016-12-28 Van Andel Research Institute Peptides de l'hormone parathyroïdienne et peptides de la protéine apparentée à l'hormone parathyroïdienne ainsi que des procédés d'utilisation
US20120191039A1 (en) 2009-07-31 2012-07-26 Ascendis Pharma A/S Carrier linked pramipexole prodrugs
RU2554854C9 (ru) 2009-07-31 2017-02-03 Асцендис Фарма Ас Биоразлагаемые нерастворимые в воде гидрогели на основе полиэтиленгликоля
SG178195A1 (en) 2009-07-31 2012-03-29 Sanofi Aventis Deutschland Long acting insulin composition
US9173953B2 (en) 2009-07-31 2015-11-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
WO2011012723A1 (fr) 2009-07-31 2011-02-03 Ascendis Pharma As Compositions injectables à libération prolongée contenant un promédicament du pramipexole
SG178193A1 (en) 2009-07-31 2012-03-29 Sanofi Aventis Deutschland Prodrugs comprising an insulin linker conjugate
US20130053405A1 (en) 2009-10-06 2013-02-28 Ulrich Hersel Carrier linked paliperidone prodrugs
CA2783296C (fr) 2009-12-15 2019-01-15 Ascendis Pharma As Composition d'hormone de croissance
US20120289571A1 (en) 2009-12-31 2012-11-15 Enzon Pharmaceuticals, Inc. Polymeric conjugates of aromatic amine containing compounds including releasable urea linker
WO2011089216A1 (fr) 2010-01-22 2011-07-28 Ascendis Pharma As Lieurs de précurseurs à base de dipeptides pour des médicaments contenant des amines aliphatiques
WO2011089215A1 (fr) 2010-01-22 2011-07-28 Ascendis Pharma As Lieurs de promédicaments à base de dipeptides pour des médicaments à teneur en amine aromatique
WO2011089214A1 (fr) 2010-01-22 2011-07-28 Ascendis Pharma As Lieurs de précurseurs à base de carbamates liés à des supports
US20110229580A1 (en) 2010-03-22 2011-09-22 Indian Institute of Technology Bombay, School of Biosciences and Bioengineering Compositions and methods for nano-in-micro particles
CN103037902A (zh) * 2010-03-29 2013-04-10 赛特克罗公司 用于降低甲状旁腺水平的方法和组合物
EP4450523A3 (fr) 2010-04-02 2025-03-12 Amunix Pharmaceuticals, Inc. Protéines de fusion de liaison, conjugués protéine de fusion-médicament de liaison, conjugués xten-médicament et leurs procédés de fabrication et d'utilisation
WO2011140392A1 (fr) 2010-05-05 2011-11-10 Prolynx Llc Supports solides pour la libération contrôlée de médicaments
ES2584381T3 (es) 2010-05-05 2016-09-27 Prolynx Llc Liberación controlada de compuestos activos desde conjugados macromoleculares
US9492508B2 (en) 2010-05-13 2016-11-15 The General Hospital Corporation Parathyroid hormone analogs and uses thereof
MX338914B (es) 2010-05-21 2016-05-06 Xl Protein Gmbh Polipeptidos biosinteticos de espira aleatoria de prolina/alanina y sus usos.
US8865220B2 (en) 2010-06-14 2014-10-21 Kaohsiung Medical University Method for controlled release of parathyroid hormone from encapsulated poly(lactic-glycolic)acid microspheres
CN102959585B (zh) 2010-06-30 2016-03-30 日本电气方案创新株式会社 属性确定方法、属性确定装置及属性确定系统
US20120040320A1 (en) 2010-08-13 2012-02-16 Nadeau Daniel A Injection Simulation Device and Methods Thereof
EP2438930A1 (fr) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Promédicaments comprenant un conjugué de liaison d'exendine
WO2013024049A1 (fr) 2011-08-12 2013-02-21 Ascendis Pharma A/S Promédicaments liés à un excipient protéique
EP2741778A1 (fr) 2011-08-12 2014-06-18 Ascendis Pharma A/S Promédicaments liés à des excipients polymériques hyperbranchés
CA2843506C (fr) 2011-08-12 2020-05-12 Ascendis Pharma A/S Promedicaments relies a des supports comprenant des liaisons ester carboxylique reversibles
US9872864B2 (en) 2011-08-12 2018-01-23 Ascendis Pharma A/S Sustained release composition of prostacyclin
EP2741781A1 (fr) 2011-08-12 2014-06-18 Ascendis Pharma A/S Promédicaments à base de tréprostinil lié à un excipient
WO2013036857A1 (fr) 2011-09-07 2013-03-14 Prolynx Llc Coupleurs au sulfone
RU2014118642A (ru) 2011-10-12 2015-11-20 Асцендис Фарма Офтальмолоджи Дивижн А/С Предотвращение и лечение глазных нарушений
US8883862B2 (en) 2012-01-12 2014-11-11 Kaohsiung Medical University Method for controlled release of parathyroid hormone from cross-linked hyaluronic acid hydrogel
WO2013108235A1 (fr) 2012-01-20 2013-07-25 Lupin Limited Formulation de pth stabilisée
AU2013254756B2 (en) 2012-04-25 2017-03-30 Ascendis Pharma A/S Prodrugs of hydroxyl-comprising drugs
US9457096B2 (en) 2012-07-06 2016-10-04 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Concet) Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery
CA2883707A1 (fr) 2012-08-28 2014-03-06 The Governors Of The University Of Alberta Parathormone, insuline, et peptides associes conjugues a des fractions de ciblage osseux, et procedes de fabrication et d'utilisation de ceux-ci
BR112015007814B1 (pt) 2012-10-11 2022-04-19 Ascendis Pharma A/S Uso de profármaco polimérico no diagnóstico, prevenção e tratamento de doenças da articulação
AU2013328785B2 (en) 2012-10-11 2016-07-21 Ascendis Pharma A/S Hydrogel prodrugs
US10519226B2 (en) 2012-10-11 2019-12-31 Ascendis Pharma Opthalmology Division A/S VEGF neutralizing prodrugs for the treatment of ocular conditions
EP2908845A1 (fr) 2012-10-17 2015-08-26 Novo Nordisk Health Care AG Acides aminés acylés par un acide gras pour l'administration d'hormone de croissance
WO2014086961A1 (fr) 2012-12-07 2014-06-12 Ascendis Pharma A/S Promédicaments prostanoïdes liés à un support
GB201303771D0 (en) 2013-03-04 2013-04-17 Midatech Ltd Nanoparticles peptide compositions
US11116849B2 (en) 2013-04-22 2021-09-14 Ascendis Pharma A/S Hydrogel-linked prodrugs releasing tagged drugs
US20150065423A1 (en) 2013-08-30 2015-03-05 Perosphere, Inc. Rapid acting injectable formulations
US10040850B2 (en) 2013-10-08 2018-08-07 Ascendis Pharma A/S Protecting group comprising a purification tag
EP2868326A1 (fr) 2013-11-04 2015-05-06 Université Pierre et Marie Curie (Paris 6) Peptides inhibiteurs de l'interaction TEAD/YAP-TAZ
EP3193941B1 (fr) * 2014-08-06 2024-05-22 Ascendis Pharma A/S Promédicaments comprenant un liant de type aminoalkylglycine
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
CA2972318A1 (fr) 2015-01-09 2016-07-14 Ascendis Pharma Growth Disorders A/S Promedicaments de facteur natriuretique de type c (cnp)
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
IL317744A (en) 2016-03-01 2025-02-01 Ascendis Pharma Bone Diseases As PTH drug agonists
HRP20230385T1 (hr) 2016-09-29 2023-06-23 Ascendis Pharma Growth Disorders A/S Kombinirana terapija sa cnp agonistima s kontroliranim oslobađanjem
FI3518982T3 (fi) 2016-09-29 2025-02-11 Ascendis Pharma Bone Diseases As Säädellysti vapautuvia PTH-yhdisteitä
PL3518961T3 (pl) * 2016-09-29 2023-08-14 Ascendis Pharma Bone Diseases A/S Związki pth o niskim stosunku wartości maksymalnej do minimalnej
RS64440B1 (sr) 2016-09-29 2023-09-29 Ascendis Pharma Bone Diseases As Režim doziranja za pth jedinjenje sa kontrolisanim oslobađanjem
TW201832783A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 包含ｇｌｐ－１／胰高血糖素雙重激動劑、連接子和透明質酸的接合物
CA3099620A1 (fr) 2018-05-18 2019-11-21 Ascendis Pharma Bone Diseases A/S Dose initiale de conjugues de la pth
US12403182B2 (en) 2019-02-11 2025-09-02 Ascendis Pharma Bone Diseases A/S Liquid pharmaceutical formulations of PTH conjugates
CN115003320A (zh) 2020-01-13 2022-09-02 阿森迪斯药物骨疾病股份有限公司 甲状旁腺功能减退的治疗

Also Published As

Publication number Publication date
EP4491239A2 (fr) 2025-01-15
WO2018060311A1 (fr) 2018-04-05
AU2017336250C1 (en) 2023-08-03
PL3518982T3 (pl) 2025-03-24
HRP20250102T1 (hr) 2025-03-28
AU2017336250A1 (en) 2019-03-21
AU2017336250B2 (en) 2023-04-20
RS66518B1 (sr) 2025-03-31
SMT202500059T1 (it) 2025-03-12
SI3518982T1 (sl) 2025-03-31
US12453778B2 (en) 2025-10-28
AU2023202402B2 (en) 2024-09-12
ES3012647T3 (en) 2025-04-09
LT3518982T (lt) 2025-02-25
AU2024270632A1 (en) 2025-01-02
CN109789221A (zh) 2019-05-21
AU2023202402A1 (en) 2023-07-20
MA46428A (fr) 2019-08-07
EP3518982A1 (fr) 2019-08-07
JP2024037994A (ja) 2024-03-19
FI3518982T3 (fi) 2025-02-11
CN109789221B (zh) 2022-11-01
CN116059321A (zh) 2023-05-05
US20190224329A1 (en) 2019-07-25
JP2022081604A (ja) 2022-05-31
HUE070273T2 (hu) 2025-05-28
EP3518982B1 (fr) 2024-11-27
PT3518982T (pt) 2025-01-29
DK3518982T3 (da) 2025-02-03
JP7483776B2 (ja) 2024-05-15
CA3037444A1 (fr) 2018-04-05
JP7039574B2 (ja) 2022-03-22
JP2019533649A (ja) 2019-11-21
EP4491239A3 (fr) 2025-03-26

Similar Documents

Publication Publication Date Title
EP4491239A3 (fr) Dosage incrémentiel dans des composés pth à libération contrôlée
NZ751969A (en) Dosage regimen for a controlled-release pth compound
ZA202200519B (en) Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
EA201992550A1 (ru) Фунгицидные смеси, содержащие замещенные 3-фенил-5-(трифторметил)-1,2,4-оксадиазолы
EP3895717A4 (fr) Composition pharmaceutique pour prévenir ou traiter un cancer, comprenant weissella cibaria wikim28 en tant que substance active
EP3587422A4 (fr) Composé dérivé de pyrrolo-pyrimidine, son procédé de préparation, et composition pharmaceutique comprenant ledit composé en tant que principe actif pour la prévention ou le traitement d'une maladie liée à la protéine kinase
MA40768B1 (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
PE20200740A1 (es) Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton
PH12021550554A1 (en) N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors
EP3417853A4 (fr) Composition pharmaceutique pour le traitement d'un cancer, contenant un composé polyphénol utilisé comme principe actif
HRP20221150T1 (hr) Semaglutid u kardiovaskularnim stanjima
WO2019018451A3 (fr) Compositions et méthodes de prévention et de traitement d'effets de proximité induits par rayonnement provoqués par un rayonnement ou une radiothérapie
MX2023011203A (es) Derivado de cumarina para terapia o profilaxis de un trastorno proliferativo celular.
RU2019121690A (ru) Дексмедетомидин или медетомидин для применения для лечения сепарационной тревожности у собак
EP3698801A4 (fr) Composition pharmaceutique pour prévenir et traiter le diabète contenant un sel de zinc, un cyclo-hispro et un antidiabétique à titre de principes actifs
RU2017129068A (ru) Способ лечения или профилактики атеротромботических явлений у пациентов с инфарктом миокарда в анамнезе
EP3778555A4 (fr) Nouveau composé et composition pharmaceutique pour prévenir ou traiter l'obésité ou le syndrome métabolique comprenant celui-ci
BR112021025288A2 (pt) Composição fungicida sinergística
MA46343B1 (fr) Schéma posologique pour composé pth à libération controlée
MX2025004084A (es) Uso de dosis mas altas de formulaciones de huperzina de liberacion modificada
EP4023234A4 (fr) Composition pharmaceutique pour le traitement d'un cancer, contenant un composé polyphénol utilisé comme principe actif
MY198417A (en) Use of Carbamate Compound for Preventing, Alleviating, or Treating Tremors or Tremor Syndrome
MA49396A (fr) Traitement de la migraine avec acétyl-leucine
EA032385B9 (ru) Фармацевтическая композиция для лечения заболеваний желудочно-кишечного тракта